Comparison of Antiplatelet Effect and Safety of Clopidogrel Napadisilate with Clopidogrel Bisulfate in Coronary Artery Disease Patients: Multi-center, Randomized, Double-blind, Phase IV, Non-inferiority Clinical Trial

被引:3
|
作者
Lee, Sahmin [1 ]
Lee, Hae-Young [1 ]
Park, Kyung-Woo [1 ]
Kang, Hyun-Jae [1 ]
Koo, Bon-Kwon [1 ]
Kim, Hyo-Soo [1 ]
Choi, Dong-Ju [2 ]
Kim, Myung-A [3 ]
Oh, Byung-Hee [1 ,4 ]
机构
[1] Seoul Natl Univ Hosp, Dept Cardiol, Seoul 110744, South Korea
[2] Seoul Natl Univ, Bundang Hosp, Dept Cardiol, Seoul 110744, South Korea
[3] Boramae Med Ctr, Dept Cardiol, Seoul, South Korea
[4] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 110744, South Korea
关键词
MONITORING PLATELET INHIBITION; ELUTING STENT IMPLANTATION; ST-SEGMENT ELEVATION; THROMBOSIS; DRUG; THERAPY; ASPIRIN; REACTIVITY; GUIDELINES; RISK;
D O I
10.1007/s40256-013-0039-y
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Clopidogrel napadisilate has better clopidogrel stability than clopidogrel bisulfate. There are no data, however, on the antiplatelet efficacy and tolerability of clopidogrel napadisilate in coronary artery disease (CAD) patients. The aim of this study is to demonstrate that the combination therapy of aspirin and clopidogrel napadisilate is not inferior to that of aspirin and clopidogrel bisulfate with respect to its effectiveness in inhibiting platelet aggregation, if it is given for 4 weeks to CAD patients who had been treated with a drug-eluting stent more than 12 months prior and had remained in a stable condition with a single antiplatelet agent, aspirin. This study was a prospective, randomized, double-blind, double-dummy, parallel-group, phase IV clinical trial. A total of 162 patients were prospectively recruited from three centers. The subjects were randomized to either the test group that was treated with 75 mg of clopidogrel napadisilate once daily or to the control group that was treated with 75 mg of clopidogrel bisulfate once daily. The primary outcome was the percent inhibition of the platelet aggregation change after the medication, as assessed by a VerifyNow (TM) P2Y12 assay. The secondary outcome was the change in P2Y12 reaction units (PRUs) from the baseline to the end of 4 weeks of treatment. The prevalence of adverse events was assessed at each visit through a direct interview. The mean increase in the percent inhibition after 4 weeks of treatment was 19.4 % in the clopidogrel napadisilate group and 19.5 % in the clopidogrel bisulfate group. The lower bound of the 95 % two-sided confidence interval for the difference in the change between the two groups (-5.46) was greater than the pre-defined non-inferiority margin of (-10.5). Therefore, clopidogrel napadisilate was deemed non-inferior to clopidogrel bisulfate with respect to its effectiveness in inhibiting platelet aggregation. The PRU decreased by 73.1 +/- A 30.7 in the clopidogrel napadisilate group, which decreased by -7.8 more than in the clopidogrel bisulfate group (65.3 +/- A 62.1); but the difference between the two groups was statistically insignificant (p = 0.435). There was no significant difference in the drug-related adverse events between the two groups (12.3 vs. 10.1 %; p = 0.804). The platelet inhibitory efficacy of clopidogrel napadisilate is not inferior to that of clopidogrel bisulfate. There were also no statistically significant differences between the two treatment groups in the safety analyses. Therefore, clopidogrel napadisilate can be a suitable alternative to clopidogrel bisulfate in stable CAD patients who have undergone a drug-eluting stent placement. Registered at ClinicalTrials.gov as NCT01830491.
引用
收藏
页码:413 / 424
页数:12
相关论文
共 50 条
  • [1] Comparison of Antiplatelet Effect and Safety of Clopidogrel Napadisilate with Clopidogrel Bisulfate in Coronary Artery Disease Patients: Multi-center, Randomized, Double-blind, Phase IV, Non-inferiority Clinical Trial
    Sahmin Lee
    Hae-Young Lee
    Kyung-Woo Park
    Hyun-Jae Kang
    Bon-Kwon Koo
    Hyo-Soo Kim
    Dong-Ju Choi
    Myung-A Kim
    Byung-Hee Oh
    American Journal of Cardiovascular Drugs, 2013, 13 : 413 - 424
  • [2] Comparison of Antiplatelet Effect and Safety of Clopidogrel Napadisilate with Clopidogrel Bisulfate in Stroke Patients: Multi-Center, Randomized, Open-Label, Phase IV, Non-Inferiority Clinical Trial
    Kang, K.
    Lee, S. J.
    Kim, H. J.
    Koh, S. H.
    Kim, B. K.
    CEREBROVASCULAR DISEASES, 2015, 40 : 48 - 48
  • [3] Comparison of antiplatelet effect and safety of clopidogrel napadisilate with clopidogrel bisulfate in stroke patients: multicenter, randomized, open-label, phase 4, non-inferiority clinical trial
    Kang, Kyusik
    Lee, Se-Jin
    Kim, Hee-Jin
    Koh, Seong-Ho
    Kim, Byung Kun
    CURRENT MEDICAL RESEARCH AND OPINION, 2016, 32 (01) : 105 - 112
  • [4] Comparison of Antiplatelet Efficacy and Tolerability of Clopidogrel Napadisilate With Clopidogrel Bisulfate in Coronary Artery Disease Patients After Percutaneous Coronary Intervention: A Prospective, Multicenter, Randomized, Open-Label, Phase IV, Noninferiority Trial
    Park, Jun-Bean
    Koo, Bon-Kwon
    Choi, Woong-Gil
    Kim, Seok-Yeon
    Park, Jinsik
    Kwan, Jun
    Park, Chang Gyu
    Kim, Hyo-Soo
    CLINICAL THERAPEUTICS, 2013, 35 (01) : 28 - 37
  • [5] Efficacy of Lafutidine Versus Famotidine in Patients with Reflux Esophagitis: A Multi-Center, Randomized, Double-Blind, Non-inferiority Phase III Trial
    Kim, Eun Hye
    Lee, Yong Chan
    Chang, Young Woon
    Park, Jong-Jae
    Chun, Hoon Jai
    Jung, Hwoon-Yong
    Kim, Hyun-Soo
    Jeong, Hyun Yong
    Seol, Sang-Young
    Han, Sok Won
    Choi, Myung-Gyu
    Park, Soo-Heon
    Lee, Ok-Jae
    Jung, Jin Tae
    Lee, Dong Ho
    Jung, Hyun Chae
    Lee, Soo Teik
    Kim, Jae Gyu
    Youn, Sei Jin
    Kim, Hak Yang
    Lee, Sang Woo
    DIGESTIVE DISEASES AND SCIENCES, 2015, 60 (06) : 1724 - 1732
  • [6] Efficacy of Lafutidine Versus Famotidine in Patients with Reflux Esophagitis: A Multi-Center, Randomized, Double-Blind, Non-inferiority Phase III Trial
    Eun Hye Kim
    Yong Chan Lee
    Young Woon Chang
    Jong-Jae Park
    Hoon Jai Chun
    Hwoon-Yong Jung
    Hyun-Soo Kim
    Hyun Yong Jeong
    Sang-Young Seol
    Sok Won Han
    Myung-Gyu Choi
    Soo-Heon Park
    Ok-Jae Lee
    Jin Tae Jung
    Dong Ho Lee
    Hyun Chae Jung
    Soo Teik Lee
    Jae Gyu Kim
    Sei Jin Youn
    Hak Yang Kim
    Sang Woo Lee
    Digestive Diseases and Sciences, 2015, 60 : 1724 - 1732
  • [7] The efficacy and safety of ciprofol versus propofol for deep sedation during colonoscopy: A phase III, multi-center, randomized, double-blind, non-inferiority trial
    Li Junxiang
    Wang Xiao
    Liu Jin
    Wang Xia
    Zuo YunXia
    ANESTHESIA AND ANALGESIA, 2021, 133 (3S_SUPPL): : 264 - 264
  • [8] A Randomized Double-Blind Study to Assess the Onset and Offset of the Antiplatelet Effects of Ticagrelor versus Clopidogrel in Patients With Stable Coronary Artery Disease
    Gurbel, Paul
    Bliden, Kevin
    Butler, Kathleen
    Tantry, Udaya
    Teng, Renli
    Antonino, Mark
    Patil, Shankar B.
    Karunakaran, Arun
    Kereiakes, Dean
    Paris, Cordel
    Purdy, Drew
    Saucedo, Jorge
    Wilson, Vance
    Ledley, Gary
    Storey, Robert F.
    CIRCULATION, 2009, 120 (18) : S1143 - S1143
  • [9] MILDRONATE VERSUS LEVOCARNITINE IN PATIENTS WITH ISCHEMIC HEART DISEASE: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, NON-INFERIORITY TRIAL
    Shu, M. Q.
    Song, Z. Y.
    Jing, T.
    Zhang, Q.
    Song, Y. M.
    Zhang, Y.
    Yang, C. M.
    Zhang, H.
    Yin, Y. H.
    Liu, D.
    Hao, Y. M.
    Liu, F.
    Zheng, Q.
    Xiao, J. F.
    Li, X. T.
    Fu, H.
    Chen, Y.
    She, B. R.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2014, 115 : 2 - 2
  • [10] Comparison of TachoSil and TachoComb in patients undergoing liver resection—a randomized, double-blind, non-inferiority trial
    S. Kawasaki
    H. Origasa
    V. Tetens
    M. Kobayashi
    Langenbeck's Archives of Surgery, 2017, 402 : 591 - 598